Literature DB >> 8895507

Metastasis of mammary carcinomas in GRS/A hybrid mice transgenic for the mts1 gene.

N S Ambartsumian1, M S Grigorian, I F Larsen, O Karlstrøm, N Sidenius, J Rygaard, G Georgiev, E Lukanidin.   

Abstract

Transgenic mice, carrying the mts1 gene, one of the genes involved in the acquisition of the metastatic phenotype, were generated. The mts1 gene was placed under the control of the mouse mammary tumor virus (MMTV) long terminal repeat (LTR) promoter leading to overexpression in the lactating mammary gland of transgenic animals. Animals bearing the transgene appear phenotypically normal. Animals of two transgenic lines (Tg463 and Tg507) were crossed with the GRS/A mice. The GRS/A strain is characterized by high incidence of mammary tumors which rarely metastasize. 40% of the tumor bearing hybrid GRS/A mts1 females were found to develop secondary tumors in the lungs. The Mts1 protein was detected in the transgene primary tumor cells as well as in the corresponding metastases. Nontransgenic littermates expressed the Mts1 protein only in the stromal cells surrounding the tumor but not in the tumor cells by itself. Taken together these observations indicate that overexpression of the mts1 gene in the mouse mammary carcinoma cells gives rise to more aggressive tumors which are able to metastasize.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8895507

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  50 in total

1.  Hypomethylation of the metastasis-associated S100A4 gene correlates with gene activation in human colon adenocarcinoma cell lines.

Authors:  N Nakamura; K Takenaga
Journal:  Clin Exp Metastasis       Date:  1998-07       Impact factor: 5.150

2.  Protein S100A4: too long overlooked by pathologists?

Authors:  Luca Mazzucchelli
Journal:  Am J Pathol       Date:  2002-01       Impact factor: 4.307

3.  Crystal structure of the S100A4-nonmuscle myosin IIA tail fragment complex reveals an asymmetric target binding mechanism.

Authors:  Bence Kiss; Annette Duelli; László Radnai; Katalin A Kékesi; Gergely Katona; László Nyitray
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-28       Impact factor: 11.205

4.  S100A4 downregulates filopodia formation through increased dynamic instability.

Authors:  Connie Goh Then Sin; Nils Hersch; Philip S Rudland; Roger Barraclough; Bernd Hoffmann; Stephane R Gross
Journal:  Cell Adh Migr       Date:  2011 Sep-Oct       Impact factor: 3.405

5.  The metastasis-promoting protein S100A4 regulates mammary branching morphogenesis.

Authors:  Kristin Andersen; Hidetoshi Mori; Jimmie Fata; Jamie Bascom; Tove Oyjord; Gunhild M Mælandsmo; Mina Bissell
Journal:  Dev Biol       Date:  2010-12-31       Impact factor: 3.582

6.  PTCSC3 Is Involved in Papillary Thyroid Carcinoma Development by Modulating S100A4 Gene Expression.

Authors:  Jaroslaw Jendrzejewski; Andrew Thomas; Sandya Liyanarachchi; Andrew Eiterman; Jerneja Tomsic; Huiling He; Hanna S Radomska; Wei Li; Rebecca Nagy; Krzysztof Sworczak; Albert de la Chapelle
Journal:  J Clin Endocrinol Metab       Date:  2015-08-14       Impact factor: 5.958

7.  Proteins of the S100 family regulate the oligomerization of p53 tumor suppressor.

Authors:  Maria Rosario Fernandez-Fernandez; Dmitry B Veprintsev; Alan R Fersht
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-21       Impact factor: 11.205

8.  Integrin alpha6beta4 controls the expression of genes associated with cell motility, invasion, and metastasis, including S100A4/metastasin.

Authors:  Min Chen; Mala Sinha; Bruce A Luxon; Anne R Bresnick; Kathleen L O'Connor
Journal:  J Biol Chem       Date:  2008-11-14       Impact factor: 5.157

Review 9.  S100A4 and metastasis: a small actor playing many roles.

Authors:  Kjetil Boye; Gunhild M Maelandsmo
Journal:  Am J Pathol       Date:  2009-12-17       Impact factor: 4.307

10.  S100A4 mediates endometrial cancer invasion and is a target of TGF-beta1 signaling.

Authors:  Ran Xie; Matthew P Schlumbrecht; Gregory L Shipley; Susu Xie; Roland L Bassett; Russell R Broaddus
Journal:  Lab Invest       Date:  2009-06-08       Impact factor: 5.662

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.